LCG
ITCI

Lisanti Capital Growth’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Lisanti Capital Growth’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-72,600
Closed -$6.06M – 165
2024
Q4 		$6.06M Buy
72,600
+14,485
+25% +$1.19M 1.46% 16
2024
Q3 		$4.25M Sell
58,115
-24,760
-30% -$1.86M 1.08% 39
2024
Q2 		$5.68M Buy
82,875
+29,590
+56% +$2.05M 1.36% 23
2024
Q1 		$3.69M Buy
53,285
+400
+0.8% +$27.5K 0.9% 52
2023
Q4 		$3.79M Buy
+52,885
New +$3.04M 0.89% 51
2023
Q3 		– Sell
-112,650
Closed -$7.13M – 183
2023
Q2 		$7.13M Buy
112,650
+49,140
+77% +$3.06M 0.99% 37
2023
Q1 		$3.44M Sell
63,510
-51,024
-45% -$2.47M 0.48% 86
2022
Q4 		$6.06M Buy
114,534
+29,950
+35% +$1.5M 0.83% 47
2022
Q3 		$3.94M Sell
84,584
-243,310
-74% -$12.7M 0.53% 76
2022
Q2 		$18.7M Buy
327,894
+49,499
+18% +$2.81M 2.54% 2
2022
Q1 		$17M Buy
+278,395
New +$14.5M 1.91% 9
2016
Q3 		– Sell
-12,260
Closed -$476K – 112
2016
Q2 		$476K Buy
+12,260
New +$441K 0.72% 67

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Lisanti Capital Growth's ITCI Position: Q1 2025 in Review

Lisanti Capital Growth sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 72,600 shares — an estimated $6.06M sold.

Lisanti Capital Growth first reported a position in ITCI in Q2 2016 and held it in 12 quarters. The position peaked at $18.7M in Q2 2022. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Lisanti Capital Growth reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Lisanti Capital Growth sold 72,600 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $6.06M.
  • Lisanti Capital Growth first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 12 quarters.
  • Lisanti Capital Growth's Intra-Cellular Therapies Inc. position peaked at $18.7M in Q2 2022.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Lisanti Capital Growth's 13F filing for Q1 2025, filed 25 Apr 2025.